Research programme: vasopressin receptor antagonists - Schering-PloughAlternative Names: SCH 756491
Latest Information Update: 17 Nov 2009
At a glance
- Originator Schering-Plough
- Mechanism of Action Vasopressin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 31 Oct 2006 Preclinical trials in Anxiety disorders in USA (unspecified route)